CR 002
Alternative Names: CR002Latest Information Update: 10 Sep 2008
At a glance
- Originator Amgen; CuraGen Corporation
- Developer CuraGen Corporation
- Class Monoclonal antibodies
- Mechanism of Action Platelet-derived growth factor D antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic nephropathies; IgA nephropathy; Systemic lupus erythematosus
Most Recent Events
- 10 Sep 2008 No development reported - Phase-I for IgA nephropathy in USA (IV)
- 10 Sep 2008 No development reported - Preclinical for Diabetic nephropathies in USA (IV)
- 10 Sep 2008 No development reported - Preclinical for Systemic lupus erythematosus in USA (IV)